Original Publication Date: 1 February, 2015
Publication / Source: Future Oncology
Authors: Georgios D Lianos, Alberto Mangano, William C Cho et al.
Recent cancer progress has been too slow [1,2]. Resistance to current therapeutics represents the major problem . More recent developed technique of circulating tumor DNA (ctDNA)  detection and subsequently next-generation sequencing (NGS) application in these ‘fluid’ biopsies provides a partial explanation of therapeutic resistance due to the emergence of mutation. This mutational emerging heterogeneity assessment shapes a new roadmap for more effective therapeutic development .